NEW YORK, May 1, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=146162&from=4CLASS PERIOD: March 17 ...

Group 1 - Alvotech (NASDAQ: ALVO) was previously rated as a "Buy" with shares trading at $12, ending 2024 at approximately $13.5, but has seen a significant decline since mid-February [2] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts, buy and sell ratings, product sales forecasts, and detailed financial analyses [2] - The analyst, Edmund Ingham, has over 5 years of experience in biotech, healthcare, and pharma, having compiled detailed reports on over 1,000 companies [2]

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

Financial Data and Key Metrics Changes - Ionis Pharmaceuticals increased its 2025 financial guidance across all metrics, raising revenue expectations by more than 20% due to strong Q1 results and successful licensing transactions [31][36] - The company reported $132 million in revenue for Q1 2025, a 10% year-over-year increase, with over half of the revenue coming from commercial products, which grew 28% compared to the same period last year [31][34] - Non-GAAP operating expenses increased by less than 5%, reflecting disciplined investment and driving operating leverage [34][39] Business Line Data and Key Metrics Changes - The launch of TrINGOLZA generated over $6 million in product sales in its first full quarter, exceeding expectations [32][33] - SPINRAZA royalties contributed $48 million, a 25% year-over-year increase, while Waynua royalties amounted to $9 million, with expectations for growth driven by strong US demand [33][34] - The company is on track to add initial product revenue from the upcoming launch of Donadolorsen, with an FDA action date set for August 21 [37][38] Market Data and Key Metrics Changes - The initial prescriber mix for TrINGOLZA included approximately 50% cardiologists and 25% endocrinologists, with positive feedback from physicians regarding patient outcomes [15][14] - The company is focusing on patient finding efforts and healthcare provider education to increase awareness of familial chylomicronemia syndrome (FCS) and hereditary angioedema (HAE) [18][27] Company Strategy and Development Direction - Ionis is focused on executing strategic priorities, including multiple independent launches and expanding its pipeline of transformational medicines [7][11] - The company aims to leverage its first independent launch to build momentum for future launches, including Donadolorsen and olazarcen, which are expected to address significant unmet medical needs [10][12] - Ionis is committed to driving long-term value for shareholders through sustained revenue growth and positive cash flow [41][44] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the rapidly evolving environment, including changes at the FDA and new tariff policies, which introduce uncertainty but do not currently impact the business [6][62] - The company expressed confidence in its ability to deliver transformational medicines and achieve substantial revenue growth despite external challenges [9][41] - Ionis expects to generate over $3 billion in peak annual product sales from its owned medicines and over $2 billion from partnered medicines, positioning the company for significant top-line growth [40][41] Other Important Information - Ionis completed licensing transactions for sapaglutzin and ex-US commercialization rights for olazarcen, enhancing its financial outlook and enabling a focus on independent launches [36][38] - The company is actively engaging with payers to ensure broad access for patients and is monitoring the impact of tariffs on its operations [16][62] Q&A Session Summary Question: Overlap between physician prescribers for FCS and SHTG - Management indicated significant overlap among prescribers, with cardiologists and endocrinologists treating both FCS and SHTG patients, which presents an opportunity for growth [46][49] Question: Confidence in FCS patient estimates and conversion to commercial therapy - Management expressed confidence in the estimate of over 3,000 FCS patients and noted that awareness efforts are expected to drive patient identification and conversion to commercial therapy [67][70] Question: Impact of Medicare Part D redesign on uptake - Management highlighted that the redesign is expected to increase patient starts and compliance due to reduced out-of-pocket costs, positively impacting revenue growth [95] Question: Channel stocking for TrINGOLZA - Management confirmed that TrINGOLZA sales are demand-driven with no significant channel stocking, ensuring inventory levels are managed effectively [75][78] Question: Manufacturing footprint and exposure to tariffs - Management stated that the company has a robust manufacturing supply chain in place and has not experienced any meaningful impacts from tariffs to date [80][81]

Financial Data and Key Metrics Changes - The company generated net investment income (NII) of $0.27 per share, consistent with the previous quarter but down from $0.38 per share in the same quarter last year [26] - The net asset value (NAV) decreased to $7.57 per share from $8.43 at the end of the previous quarter and $9.64 a year ago, primarily due to fair value adjustments and distributions [27] - Investment income for the first quarter was $25 million, slightly down from $26 million in the prior year period, attributed to lower interest and fee income [24] Business Line Data and Key Metrics Changes - The portfolio at the end of the first quarter stood at $690 million, with new debt investments totaling $100 million and equity investments of $2 million [11] - The debt portfolio yield was 15% for the quarter, compared to 15.6% in the same quarter last year, while onboarding yields were 13%, up from 12.6% in the previous quarter [24][12] - The company funded nine debt investments during the quarter, with a significant portion directed towards life science and technology sectors [11] Market Data and Key Metrics Changes - Approximately $92 billion was invested in VC-backed companies in the first quarter, marking a 19% increase from the previous quarter, driven largely by large AI deals [17] - The exit market for VC-backed tech and life science companies remains nearly shut due to tariff-related uncertainties, impacting investor sentiment [18] - The S&P Biotech Select Industry Index is down 14% year over year, reflecting cooling investor sentiment in the life sciences market [18] Company Strategy and Development Direction - The company aims to grow its portfolio while maintaining a focus on high-quality investments, particularly in the tech and life science sectors [10] - The management remains selective in originating loans due to the current macroeconomic environment, with a commitment to optimizing returns from stressed investments [15] - The partnership with Monroe Capital is expected to enhance capital access and operational support, aiding in portfolio growth [9] Management's Comments on Operating Environment and Future Outlook - The management expressed guarded optimism for 2025, despite macroeconomic headwinds impacting recovery from stressed assets [6] - The company anticipates that the venture debt market will remain active, providing opportunities for investment despite current challenges [10] - Management highlighted the importance of maintaining strong liquidity and a robust balance sheet to navigate the current environment [23] Other Important Information - The company declared regular monthly distributions of $0.11 per share through September 2025, supported by undistributed spillover income of $1 per share [7][26] - The company has a committed backlog of $236 million, providing a solid base for future portfolio growth [8] Q&A Session Summary Question: How is the company managing spillover earnings in the current uncertain environment? - The company plans to continue growing distributions through 2025 and will manage spillover earnings quarterly, with confidence in covering distributions over time [32][34] Question: What is the quality of deals currently being pursued? - The company is seeing a higher bar for transaction selection, focusing on companies with strong operational performance and quality VC backing [36][37] Question: Will the company raise leverage ratios to grow the portfolio? - The target leverage ratio is around 1.2x to 1.3x, with the current ratio at 1.29x, indicating a cautious approach to leverage [41] Question: Is there any discussion about cutting the base management fee? - The company’s base management fee is competitive with industry standards, and it is reviewed regularly [43] Question: How does the company plan to address the frozen market conditions? - The company is focusing on generating yield through higher returns from existing portfolio companies rather than relying on warrant expectations [55][52] Question: What is the impact of tariffs on the portfolio? - The primary impact of tariffs is the uncertainty they create, affecting market transactions rather than direct exposure to specific tariffs [63] Question: Has the partnership with Monroe Capital provided additional resources? - The partnership is expected to enhance operational support and focus on stabilizing and growing the business [66]

Core Insights - Senti Biosciences, Inc. announced positive preliminary clinical results for its lead program, SENTI-202, targeting Relapsed/Refractory AML [1] - The company will present these results at the Citizens JMP Life Sciences Conference on May 8, 2025, in New York [1][2] - Senti Bio is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] Company Overview - Senti Bio is a clinical-stage biotechnology company dedicated to creating innovative cell and gene therapies for patients with incurable diseases [3] - The company utilizes a synthetic biology platform to engineer Gene Circuits that enhance precision and control in targeting cancer cells while sparing healthy cells [3] - Senti Bio's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [3]

Financial Data and Key Metrics Changes - The company generated net investment income (NII) of $0.27 per share, unchanged from the previous quarter but down from $0.38 per share in the same quarter last year [27] - The net asset value (NAV) decreased to $7.57 per share from $8.43 at the end of the previous quarter and $9.64 a year ago, primarily due to fair value adjustments and distributions [28] - Investment income for the first quarter was $25 million, a slight decrease from $26 million in the prior year period, attributed to lower interest and fee income [25] Business Line Data and Key Metrics Changes - The total investment portfolio at the end of the first quarter stood at $690 million, with debt investments in 53 companies valued at $644 million and equity investments in 110 companies valued at $46 million [27] - New originations totaled $102 million, offset by $11 million in scheduled principal payments and $68 million in prepayments [27] - The debt portfolio yield was 15%, slightly down from 15.6% in the same quarter last year, while onboarding yields were 13%, up from 12.6% in the previous quarter [25][12] Market Data and Key Metrics Changes - Approximately $92 billion was invested in VC-backed companies in the first quarter, a 19% increase from the previous quarter, driven largely by significant AI deals [18] - The S&P Biotech Select Industry Index is down 14% year-over-year, indicating cooling investor sentiment in the life sciences market [19] - The exit market for VC-backed tech and life science companies remains nearly shut due to macroeconomic uncertainties, impacting the overall venture capital ecosystem [20] Company Strategy and Development Direction - The company aims to grow its portfolio while maintaining a focus on high-quality, well-sponsored tech and life science companies [20] - The management remains selective in originating loans due to the current macro environment, with a commitment to optimizing returns from stressed investments [16] - The partnership with Monroe Capital is expected to provide additional capital and scale, enhancing the company's ability to navigate current market challenges [9] Management's Comments on Operating Environment and Future Outlook - Management expressed guarded optimism for the year despite recent macroeconomic headwinds, including tariff-related uncertainties impacting recovery from stressed assets [5] - The company anticipates that as the macro environment normalizes, it will be positioned to grow its portfolio and increase NII to cover distributions over time [16] - Management highlighted the importance of maintaining a strong liquidity position, with $126 million in available liquidity as of March 31 [23] Other Important Information - The company declared regular monthly distributions of $0.11 per share through September 2025, supported by undistributed spillover income of $1 per share [27] - The advisor has agreed to waive a portion of its quarterly income incentive fees if NII falls below declared distributions [7] - The company is actively managing its portfolio to optimize returns and mitigate risks associated with stressed investments [15] Q&A Session Summary Question: How is the company managing spillover earnings in the current uncertain environment? - Management indicated that they plan to continue growing distributions through 2025 and will manage spillover earnings quarterly, reviewing them in discussions with the board [32][34] Question: What is the quality of deals currently being pursued? - Management noted a higher bar for selecting transactions, focusing on companies performing well operationally and backed by quality VCs, while being selective due to the current market conditions [36][38] Question: Is there a plan to raise leverage ratios to grow the portfolio? - The target leverage ratio is around 1.2x to 1.3x, with the current ratio at 1.29x, indicating a cautious approach to leverage [42][43] Question: How does the company plan to address the high dividend payout relative to debt yields? - Management stated that they review equity needs and funding pipelines quarterly, considering the balance between dividends and investment returns [47][48] Question: What is the impact of tariffs on the portfolio? - Management indicated that while there is some uncertainty due to tariffs, most portfolio companies have planned for potential impacts, and the overall effect has been more about market volatility than specific tariff issues [65][66] Question: What resources are available from the recent Monroe partnership? - The partnership is expected to provide support in stabilizing and growing the business, with ongoing collaboration to enhance operational effectiveness [68][69]

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2025. All figures are reported in Canadian dollars. The Company’s full set of consolidated audited financial statements for th ...

Core Insights - INOVIO is focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, and will present at several upcoming conferences to share new data on its lead candidate INO-3107 [1][4] Conference Presentations - INOVIO will participate in the Citizens JMP Life Sciences Conference on May 8, featuring a fireside chat format [2] - At the European Laryngological Society Annual Congress on May 9, INOVIO will present data showing that INO-3107 generates a targeted immunologic response, resulting in surgery reduction for 81% of adults with recurrent respiratory papillomatosis in the first year [2] - The American Society of Gene and Cell Therapy will host a poster abstract session on May 13, discussing the successful treatment of recurrent respiratory papillomatosis with INO-3107, regardless of papilloma microenvironment and molecular subtype [2] - An oral presentation at the ABEA program during the COSM on May 15 will focus on the durability and long-term clinical effects of INO-3107 in treating recurrent respiratory papillomatosis caused by HPV types 6 and 11 [3] Company Overview - INOVIO is a biotechnology company that specializes in the design and delivery of innovative DNA medicines, aiming to empower the body to produce its own disease-fighting tools [4]

Core Viewpoint - Alterity Therapeutics reported significant progress in its clinical trials for ATH434, a treatment for Multiple System Atrophy (MSA), highlighting its potential to change the treatment landscape for this condition [3][8]. Financial Summary - As of March 31, 2025, Alterity's cash position was A$17.96 million, with operating cash outflows of A$0.73 million for the quarter [4]. - The company raised approximately A$15.0 million during the period and an additional A$27.1 million after the quarter ended [11]. Clinical Trial Updates - The ATH434-201 Phase 2 trial demonstrated a 48% relative treatment effect at the 50 mg dose and a 30% effect at the 75 mg dose, indicating significant efficacy in reducing disease severity compared to placebo [7]. - The ATH434-202 open-label trial in advanced MSA was completed, with topline data expected to be reported mid-year 2025 [10]. Operational Activities - The ATH434-201 trial involved 77 participants and utilized wearable sensors to assess outpatient activity levels, showing clinically meaningful improvements in various metrics [6][9]. - The company plans to engage with regulatory authorities to advance ATH434's development for MSA [3]. Corporate Activities - Alterity received a refund of A$1.65 million from the Australian Taxation Office under the Research and Development Tax Incentive Scheme for eligible activities conducted in the financial year ending June 30, 2020 [11].